Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brenda F Baker

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
RNA (New York, N.Y.)|November 23, 2005
Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activityBryan A Kraynack, Brenda F Baker
Clinical Pharmacokinetics|January 7, 2015
Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein BRichard S Geary, Brenda F Baker, Stanley T Crooke
Cell Metabolism|February 7, 2019
RNA-Targeted TherapeuticsStanley T Crooke, Joseph L Witztum, C Frank Bennett, et al.
The Journal of Biological Chemistry|February 18, 2021
Antisense technology: A reviewStanley T Crooke, Xue-Hai Liang, Brenda F Baker, et al.
Nature Reviews. Drug Discovery|March 25, 2021
Antisense technology: an overview and prospectusStanley T Crooke, Brenda F Baker, Rosanne M Crooke, et al.
Cell Metabolism|April 5, 2018
RNA-Targeted TherapeuticsStanley T Crooke, Joseph L Witztum, C Frank Bennett, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2006
RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cellsThazha P Prakash, Bryan Kraynack, Brenda F Baker, et al.
Annual Review of Pharmacology and Toxicology|October 13, 2016
Pharmacology of Antisense DrugsC Frank Bennett, Brenda F Baker, Nguyen Pham, et al.
Journal of Cardiovascular Translational Research|July 17, 2013
Antisense technology: an emerging platform for cardiovascular disease therapeuticsRichard G Lee, Jeff Crosby, Brenda F Baker, et al.
Plos Biology|March 16, 2007
Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exonYimin Hua, Timothy A Vickers, Brenda F Baker, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
RNA (New York, N.Y.)|November 23, 2005
Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activityBryan A Kraynack, Brenda F Baker
Clinical Pharmacokinetics|January 7, 2015
Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein BRichard S Geary, Brenda F Baker, Stanley T Crooke
Cell Metabolism|February 7, 2019
RNA-Targeted TherapeuticsStanley T Crooke, Joseph L Witztum, C Frank Bennett, et al.
The Journal of Biological Chemistry|February 18, 2021
Antisense technology: A reviewStanley T Crooke, Xue-Hai Liang, Brenda F Baker, et al.
Nature Reviews. Drug Discovery|March 25, 2021
Antisense technology: an overview and prospectusStanley T Crooke, Brenda F Baker, Rosanne M Crooke, et al.
Cell Metabolism|April 5, 2018
RNA-Targeted TherapeuticsStanley T Crooke, Joseph L Witztum, C Frank Bennett, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2006
RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cellsThazha P Prakash, Bryan Kraynack, Brenda F Baker, et al.
Annual Review of Pharmacology and Toxicology|October 13, 2016
Pharmacology of Antisense DrugsC Frank Bennett, Brenda F Baker, Nguyen Pham, et al.
Journal of Cardiovascular Translational Research|July 17, 2013
Antisense technology: an emerging platform for cardiovascular disease therapeuticsRichard G Lee, Jeff Crosby, Brenda F Baker, et al.
Plos Biology|March 16, 2007
Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exonYimin Hua, Timothy A Vickers, Brenda F Baker, et al.
Pageof 6